All companies
Visit website
ALLERGENIS
OperatingAllerGenis, Inc.
Healthcare · Founded 2017
Next generation of food allergy testing
Post-money valuation ⓘ
$40.5M
As of Aug 2023 · from AllerGenis Non Voting Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$560,602
Across 1 round since 2023
Latest share price
$5.00
AllerGenis Non Voting Common Stock 1 offering price
Financials
FY2021–FY2023 · from SEC filings · hover any figure for its source$270K
−$3.4M
2021
$74K
−$5.0M
2022
$486K
−$2.7M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
Income statement
Revenue
$269,597
$74,139
$486,040
Cost of goods sold
$0
$574,811
$276,598
Gross margin
100%
-675%
43%
Net income
-$3,422,933
-$5,008,717
-$2,699,619
Taxes paid
$0
$0
$0
Balance sheet
Cash
$19,639
$10,031
$65,753
Accounts receivable
$10,000
$4,394
$145,474
Total assets
$368,099
$347,294
$460,410
Short-term debt
$1,496,119
$0
$0
Long-term debt
$2,942,000
$0
$0
Total liabilities
$4,438,119
$0
$0
Other
Headcount
—
5
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$40.5M
post-money
AllerGenis Non Voting Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $560.6K / $1.2MInvestors 266Post-money $40.5M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 3 annual reports (FY2023–FY2025)
266 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001973036Share price $5.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.